Radiotherapy for Non-Hodgkin's lymphoma with cardiac infiltration: A case report.
Non-Hodgkin’s lymphoma
cardiac infiltration
case report
radiotherapy
zanubrutinib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
06
2023
accepted:
02
10
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
Non-Hodgkin's lymphoma (NHL) with cardiac infiltration has a poor prognosis. The median OS of patients failing to respond to chemotherapy has been reported to be 1 month vs. 18 months in patients responding to chemotherapy. Herein, we reported a case of a 57-year-old male confirmed with diffuse large B-cell lymphoma who received radiation therapy of 150-cGy daily, administered in 30 fractions to the volume of cardiac infiltration, resulting in complete relief. Chemotherapy had no curative effect. The patient was subsequently enrolled in a clinical trial and received oral administration of zanubrutinib 80mg twice daily, after which he achieved complete remission. The progression-free survival was from diagnosis (January 7, 2020) to the follow-up (September 20, 2022), amounting to 32 months. Proper irradiation dose and timing of treatment can relieve NHL symptoms.
Sections du résumé
Background
UNASSIGNED
Non-Hodgkin's lymphoma (NHL) with cardiac infiltration has a poor prognosis. The median OS of patients failing to respond to chemotherapy has been reported to be 1 month vs. 18 months in patients responding to chemotherapy.
Case presentation
UNASSIGNED
Herein, we reported a case of a 57-year-old male confirmed with diffuse large B-cell lymphoma who received radiation therapy of 150-cGy daily, administered in 30 fractions to the volume of cardiac infiltration, resulting in complete relief. Chemotherapy had no curative effect. The patient was subsequently enrolled in a clinical trial and received oral administration of zanubrutinib 80mg twice daily, after which he achieved complete remission. The progression-free survival was from diagnosis (January 7, 2020) to the follow-up (September 20, 2022), amounting to 32 months.
Conclusion
UNASSIGNED
Proper irradiation dose and timing of treatment can relieve NHL symptoms.
Identifiants
pubmed: 37916159
doi: 10.3389/fonc.2023.1234831
pmc: PMC10616872
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1234831Informations de copyright
Copyright © 2023 Wang, Zhang, Deng, Gu, Chen, Cai and Zhao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Virchows Arch. 2002 Nov;441(5):456-61
pubmed: 12447675
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):351-352
pubmed: 32375454
Front Oncol. 2022 Jun 07;12:902643
pubmed: 35747821
Dtsch Med Wochenschr. 1991 Mar 29;116(13):491-5
pubmed: 2007379
Presse Med. 1990 Apr 14;19(15):715-8
pubmed: 2139963
Cardiovasc Pathol. 2010 Nov-Dec;19(6):343-52
pubmed: 19747857
Eur J Haematol. 2016 Nov;97(5):445-452
pubmed: 26935129